Document
type: Class

Antimycobacterial activity of UDP-galactopyranose mutase inhibitors
type: Generically Dependent Continuant
chemicalscas: ethambutol, 10054-05-4, 1070-11-7, 3577-94-4, 74-55-5; isoniazid, 54-85-3, 62229-51-0, 65979-32-0; mutase, 9047-56-7; quinine, 130-89-2, 130-95-0, 14358-44-2, 549-48-4, 549-49-5, 60-93-5, 7549-43-1; rifampicin, 13292-46-1; uridine diphosphate, 58-98-0; (4-chlorophenyl)-(1-(4-chlorophenyl)-3-hydroxy-5-methyl-1H-pyrazol-4-yl)methanone; 3-(4-iodophenyl)-2-(4-(3,4-dichlorophenyl)thiazol-2-ylamino)propionic acid; Anti-Bacterial Agents; Antitubercular Agents; Enzyme Inhibitors; Intramolecular Transferases, 5.4.-; Phenylalanine, 63-91-2; Pyrazoles; Thiazoles; UDP-galactopyranose mutase, 5.4.99.9
freetext keyword: Mycobacteria; Tuberculosis; UDP-galactopyranose mutase inhibitors (4 chlorophenyl) [1 (4 chlorophenyl) 3 hydroxy 5 methyl 1h pyrazol 4 yl]methadone; 3 (4 iodophenyl) 2 [4 (3,4 dichlorophenyl)thiazol 2 ylamino]propionic acid; antimycobacterial agent; ethambutol; isoniazid; mutase; quinine; rifampicin; unclassified drug; uridine diphosphate; uridine diphosphate galactopyranose mutase; uridine diphosphate galactopyranose mutase inhibitor; antimicrobial activity; article; bacterial strain; controlled study; drug cytotoxicity; drug potency; drug synthesis; human; human cell; Klebsiella pneumoniae; macrophage; minimum inhibitory concentration; mycobacteriosis; Mycobacterium; Mycobacterium bovis; Mycobacterium smegmatis; Mycobacterium tuberculosis; nonhuman; priority journal; protein targeting; Anti-Bacterial Agents; Antitubercular Agents; Cell Line; Enzyme Inhibitors; Humans; Intramolecular Transferases; Macrophages; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium; Mycobacterium bovis; Mycobacterium tuberculosis; Phenylalanine; Pyrazoles; Thiazoles
e iscopus: 2-s2.0-77955924196
abstract: The galactofuran region of the mycobacterial cell wall consists of alternating 5- and 6-linked β-d-galactofuranose (β-d-Gal. f) residues, essential for viability. UDP-galactofuranose (UDP-Gal. f), the donor for Gal. f, is synthesised from UDP-galactopyranose (UDP-Gal. p) by the enzyme UDP-galactopyranose mutase (UGM), which is not found in humans, rendering it a therapeutic target. The in vitro properties, i.e. enzymatic activity, antimycobacterial activity, cellular toxicity, activity in mycobacterial-infected macrophages and activity against non-replicating persistent mycobacteria, of (4-chlorophenyl)-[1-(4-chlorophenyl)-3-hydroxy-5-methyl-1H-pyrazol-4-yl]-methanone and 3-(4-iodophenyl)-2-[4-(3,4-dichlorophenyl)-thiazol-2-ylamino]-propionic acid were studied. The former compound, a pyrazole, was an inhibitor of UGM from Mycobacterium tuberculosis and Klebsiella pneumoniae and was effective against Mycobacterium smegmatis, Mycobacterium bovis BCG and M. tuberculosis but ineffective against other bacterial strains tested. This compound showed potency against mycobacteria in infected macrophages but exhibited moderate cellular toxicity and was ineffective against non-replicating persistent mycobacteria. This is the first report of a compound both with UGM inhibitory properties and broad antimycobacterial activities. The latter compound, an aminothiazole, was active against UGM from K. pneumoniae and M. tuberculosis but was ineffective against M. bovis BCG or M. tuberculosis as well as demonstrating higher cellular toxicity. These data validate the choice of UGM as a target for active antimycobacterial therapy and confirm the pyrazole compound as a viable lead candidate. © 2010 Elsevier B.V. and the International Society of Chemotherapy.
related by: authorship_14506
date time value: article date 2464
page start: 364
related by: authorship_14509
estado: published
most specific type: Article
related by: authorship_14513
type: Article
type: Continuant
origen: scopus
related by: authorship_14508
type: Entity
type: Information Content Entity
doi: 10.1016/j.ijantimicag.2010.06.030
type: Document
has publication venue: International Journal of Antimicrobial Agents
volume: 36
manufactures: Sigma
crisid: 2464
related by: authorship_14511
type: Thing
related by: authorship_14514
issue: 4
page end: 368
pmid: 20678902
related by: authorship_14512
most specific type: Document
has funding vehicle: Natural Sciences and Engineering Research Council of Canada, NSERC
related by: authorship_14510
related by: authorship_14507

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

RDF description of Antimycobacterial activity of UDP-galactopyranose mutase inhibitors - http://orbis.uaslp.mx/vivo/individual/scopus2463
rights: termsOfUse
date: 2026-08-28T02:11:33
publisher: vivo
type: Document

International Journal of Antimicrobial Agents
type: Thing
type: Information Content Entity
type: Journal
type: Generically Dependent Continuant
type: Collection
publication venue for: Antimycobacterial activity of UDP-galactopyranose mutase inhibitors
type: Document
type: Continuant
type: Entity
type: Periodical

Article
type: Class

Information Content Entity
type: Class

Natural Sciences and Engineering Research Council of Canada, NSERC
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Grant
type: Continuant
funding vehicle for: Antimycobacterial activity of UDP-galactopyranose mutase inhibitors